Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

III. Medizinische Klinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Forschungsprojekte
Ergebnisse pro Seite:  10

2022 - 2027

BURAN-Studie (#1355)
  • Dr. Jürgen

2022 - 2023

DNA
  • Dr. Borhane

2022 - 2024

A Randomized Open Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared To Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
  • Dr. med. Markus,
  • Prof. Dr. med. Georg

2021 - 2025

SFB 1292/Teilprojekt 12
  • Dr. Michael,
  • Prof. Dr. Evelyn

2021 - 2040

PACE-LUNG (#1368)
  • Dr. Jürgen

2021 - 2026

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321) (#1349)
  • Prof. Dr. med. Georg,
  • Marie-Kristin

2021 - 2026

PhaseII/III study comparing trabectedin (T) versus T plus tTF-NGR to entrap T inside the tumor in patients with metastatic and/or refractory soft tissue sarcoma (STS, 2nd line)
  • Thomas,
  • Marius

2021 - 2026

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)
  • Prof. Dr. med. Georg

2021 - 2027

A Phase 1/2a First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IMA401, a bispecific T cell engaging receptor molecule (TCER®) in patients with recurrent and/or refractory solid tumors.
  • Marius,
  • Dr. med. Alexander

2021 - 2027

Pre-Screening for A Phase Ia/Ib first-in-human clinical trial to evaluate the safety, tolerability and Initial anti-tumor activity of IMA401, a bispecific T cell engaging receptor molecule (TCER®), in patients with recurrent and/or refractory solid tumors
  • Marius,
  • Dr. med. Alexander